DrugBank 5.0: a major update to the DrugBank database for 2018
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
DrugBank (www.drugbank.ca) is a web-enabled database containing comprehensive molecular information about drugs, their mechanisms, their interactions and their targets. First described in 2006, DrugBank has continued to evolve over the past 12 years in response to marked improvements to web standards and changing needs for drug research and development. This year's update, DrugBank 5.0, represents the most significant upgrade to the database in more than 10 years. In many cases, existing data content has grown by 100% or more over the last update. For instance, the total number of investigational drugs in the database has grown by almost 300%, the number of drug-drug interactions has grown by nearly 600% and the number of SNP-associated drug effects has grown more than 3000%. Significant improvements have been made to the quantity, quality and consistency of drug indications, drug binding data as well as drug-drug and drug-food interactions. A great deal of brand new data have also been added to DrugBank 5.0. This includes information on the influence of hundreds of drugs on metabolite levels (pharmacometabolomics), gene expression levels (pharmacotranscriptomics) and protein expression levels (pharmacoprotoemics). New data have also been added on the status of hundreds of new drug clinical trials and existing drug repurposing trials. Many other important improvements in the content, interface and performance of the DrugBank website have been made and these should greatly enhance its ease of use, utility and potential applications in many areas of pharmacological research, pharmaceutical science and drug education.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“DrugBank primarily contains drug indications extracted from drug labels, while MEDI utilizes public internet sources to drug indications, and is a well utilized resource of drug indications.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, we searched DrugBank84 to identify therapeutic compounds targeting AD-associated proteins. Of the 38 proteins, 15 had reported molecules (Fig. 4D).”
From Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer’s disease (2024) · cites this paper as [84]
In the citing paper
“AVPR2 and NPR1 genes play pivotal roles in regulating fluid and electrolyte balance via complementary but distinct pathways. AVPR2 contributes to water retention and urine concentration, whereas NPR1 facilitates vasodilatation, lowers blood pressure and enhances water excretion47.”
From A foundation model for clinician-centered drug repurposing (2024) · cites this paper as [47]
In the citing paper
“In essence, the CC is an alternative representation of the small-molecule knowledge deposited in the public domain and, as such, it is also limited by the availability of experimental data and the coverage of its source databases (e.g., ChEMBL9 or DrugBank10).”
From Bioactivity descriptors for uncharacterized chemical compounds (2021) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892 · cited 1×
“DrugBank 1.0, released in 2006, provided novel (at the time) physico-chemical data on selected FDA-approved drugs and their drug-targets (2).”
BackgroundInfluentialSelf-citationDrugBank: a knowledgebase for drugs, drug actions and drug targets
Wishart, D. S., Knox, C., Guo, A. C., Cheng, D., Shrivastava, S., Tzur, D., Gautam, B., & Hassanali, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm958 · Cited by 2,861 · cited 1×
“DrugBank 2.0, released in 2008, added pharmacological, pharmacogenomic and molecular biological data (3).”
BackgroundInfluentialSelf-citationThe new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog)
MacArthur, J., Bowler, E., Cerezo, M., Gil, L., Hall, P., Hastings, E., Junkins, H., McMahon, A., Milano, A., Morales, J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1133 · Cited by 2,161 · cited 2×
“org and FDA labels), as well as material collated from sources such as The Human Cytochrome P450 (CYP) Allele Nomenclature Database (12) and the NHGRI-EBI GWAS Catalog (13).”
BackgroundDrugBank 4.0: shedding new light on drug metabolism
Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1068 · Cited by 1,993 · cited 1×
“tion, distribution, metabolism, excretion and toxicity) data (5).”
Self-citationDrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1126 · Cited by 1,831 · cited 1×
“DrugBank 3.0, released in 2010, added drug–drug and drug–food interactions, drug transporter data as well as pharmacokinetic information (4).”
BackgroundInfluentialSelf-citationClassyFire: automated chemical classification with a comprehensive, computable taxonomy
Djoumbou Feunang, Y., Eisner, R., Knox, C., Chepelev, L., Hastings, J., Owen, G., Fahy, E., Steinbeck, C., Subramanian, S., Bolton, E., et al. (2016) · Journal of Cheminformatics · doi:10.1186/s13321-016-0174-y · Cited by 1,525
Self-citationThe Comparative Toxicogenomics Database: update 2017
Davis, A. P., Grondin, C. J., Johnson, R. J., Sciaky, D., King, B. L., McMorran, R., Wiegers, J., Wiegers, T. C., & Mattingly, C. J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw838 · Cited by 544 · cited 1×
“Additional pharmacoproteomic and pharmacotranscriptomic data were obtained from the CTD (18).”
MethodPredicting drug metabolism: experiment and/or computation?
Kirchmair, J., Göller, A. H., Lang, D., Kunze, J., Testa, B., Wilson, I. D., Glen, R. C., & Schneider, G. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4581 · Cited by 502 · cited 1×
“It has also become much more robust and sophisticated (21).”
BackgroundAllen, F., Pon, A., Wilson, M., Greiner, R., & Wishart, D. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku436 · Cited by 464 · cited 7×
“In particular, CFM-ID (19) and CFM-ID 2.”
BackgroundInfluentialSelf-citationSim, S. C., & Ingelman-Sundberg, M. (2010) · Human Genomics · doi:10.1186/1479-7364-4-4-278 · Cited by 216 · cited 2×
“org and FDA labels), as well as material collated from sources such as The Human Cytochrome P450 (CYP) Allele Nomenclature Database (12) and the NHGRI-EBI GWAS Catalog (13).”
Background
Cited by
Items 201–300 of 1,056
Informatics and Computational Methods in Natural Product Drug Discovery: A Review and Perspectives
Romano, J. D., & Tatonetti, N. P. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00368 · Cited by 175
“Some of these linked resources include DrugBank (Wishart et al., 2017), UniProtKB/Swiss-Prot (and associated annotation programs like ToxProt) (Jungo et al.”
BackgroundInfluentialExploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing
Sadegh, S., Matschinske, J., Blumenthal, D. B., Galindez, G., Kacprowski, T., List, M., Nasirigerdeh, R., Oubounyt, M., Pichlmair, A., Rose, T. D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17189-2 · Cited by 167
Exploring Chemical Information in PubChem
Kim, S. (2021) · Current Protocols · doi:10.1002/cpz1.217 · Cited by 163
“The chemical-protein and chemical-gene interaction data in PubChem originate from multiple sources, such as DrugBank (Wishart et al., 2018), Comparative Toxicogenomics Database (CTD; Davis et al., 2021), Drug-Gene Interaction Database (DGIdb; Freshour et al., 2021), IUPHAR/BPS Guide to PHARMACOLOGY…”
MethodDrug-Drug Interaction Predicting by Neural Network Using Integrated Similarity
Rohani, N., & Eslahchi, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-50121-3 · Cited by 175
Recent Advances in the Prediction of Pharmacokinetics Properties in Drug Design Studies: A Review
Pantaleão, S. Q., Fernandes, P. O., Gonçalves, J. E., Maltarollo, V. G., & Honorio, K. M. (2022) · ChemMedChem · doi:10.1002/cmdc.202100542 · Cited by 173
Zhao, B.-W., Hu, L., You, Z.-H., Wang, L., & Su, X.-R. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab515 · Cited by 175
Recent Advances in Machine-Learning-Based Chemoinformatics: A Comprehensive Review
Niazi, S. K., & Mariam, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411488 · Cited by 158
“Furthermore, chemical bioactivity and structural data can be acquired from drug databases like ChEMBL [21], BindingDB [22], DrugBank [23], Inxight [24], and Protein Data Bank [25].”
BackgroundMolecular design in drug discovery: a comprehensive review of deep generative models
Cheng, Y., Gong, Y., Liu, Y., Song, B., & Zou, Q. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab344 · Cited by 169
Self-citationCirculating inflammatory cytokines and risk of five cancers: a Mendelian randomization analysis
Bouras, E., Karhunen, V., Gill, D., Huang, J., Haycock, P. C., Gunter, M. J., Johansson, M., Brennan, P., Key, T., Lewis, S. J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-021-02193-0 · Cited by 171
Lou, B., & Wu, L. (2021) · MIS Quarterly · doi:10.25300/misq/2021/16565 · Cited by 177
“We also use the free text in the DrugBank database that contains comprehensive information about how each drug works (Wishart et al. 2018; Wishart et al. 2008) to ascertain the drug mechanism.2”
Generative machine learning for de novo drug discovery: A systematic review
Martinelli, D. D. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105403 · Cited by 177
Chung, Y., Vermeire, F. H., Wu, H., Walker, P. J., Abraham, M. H., & Green, W. H. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01103 · Cited by 172
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Androutsakos, T., Nasiri-Ansari, N., Bakasis, A.-D., Kyrou, I., Efstathopoulos, E., Randeva, H. S., & Kassi, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063107 · Cited by 165
“The structure of phlorizin and currently FDA-approved SGLT-2 inhibitors in the United States, including dapagliflozin, canagliflozin, empagliflozin, and ertugliflozin, along with their chemical formulae and brand names are presented in Figure 2 [78].”
Li, Z., Zhu, S., Shao, B., Zeng, X., Wang, T., & Liu, T.-Y. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbac597 · Cited by 169
Chand, A., Sahoo, D. K., Rana, A., Jena, S., & Biswal, H. S. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00289 · Cited by 173
Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay
Jang, W. D., Jeon, S., Kim, S., & Lee, S. Y. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2024302118 · Cited by 171
“A compound library of approved and clinical trial drugs retrieved from Drug-Bank (27), ZINC15 (28), and ChEMBL (29), was screened against SARS-CoV-2 M pro .”
de Bruyn Kops, C., Šícho, M., Mazzolari, A., & Kirchmair, J. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00224 · Cited by 161
A knowledge-guided pre-training framework for improving molecular representation learning
Li, H., Zhang, R., Min, Y., Ma, D., Zhao, D., & Zeng, J. (2023) · Nature Communications · doi:10.1038/s41467-023-43214-1 · Cited by 159
“More speci fi cally, we fi rst obtained 2718 US Food and Drug Administration-approved (FDA) drugs (denoted as the FDA dataset) collected from DrugBank 76 .”
Identification of disease treatment mechanisms through the multiscale interactome
Ruiz, C., Zitnik, M., & Leskovec, J. (2021) · Nature Communications · doi:10.1038/s41467-021-21770-8 · Cited by 172
Caufield, J. H., Hegde, H., Emonet, V., Harris, N. L., Joachimiak, M. P., Matentzoglu, N., Kim, H., Moxon, S., Reese, J. T., Haendel, M. A., et al. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae104 · Cited by 120
“Grounding was performed using multiple ontologies beyond MeSH, including three resources for chemical and drug information: Chemical Entities of Biological Interest (ChEBI) [23], DrugBank [24], and MedDRA [25] (See Table S1 for a full list of external resources used for grounding).”
MethodPharmKG: a dedicated knowledge graph benchmark for bomedical data mining
Zheng, S., Rao, J., Song, Y., Zhang, J., Xiao, X., Fang, E. F., Yang, Y., & Niu, Z. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa344 · Cited by 165
Pyridones in drug discovery: Recent advances
Zhang, Y., & Pike, A. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.127849 · Cited by 162
A review of biomedical datasets relating to drug discovery: a knowledge graph perspective
Bonner, S., Barrett, I. P., Ye, C., Swiers, R., Engkvist, O., Bender, A., Hoyt, C. T., & Hamilton, W. L. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac404 · Cited by 198
Gimeno, A., Mestres-Truyol, J., Ojeda-Montes, M. J., Macip, G., Saldivar-Espinoza, B., Cereto-Massagué, A., Pujadas, G., & Garcia-Vallvé, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113793 · Cited by 165
“However, since according to the DrugBank database [36], ethyl biscoumacetate was withdrawn from the market and it can produce prolonged bleeding and severe hemorrhage, the risk-benefit ratio of this treatment option should be evaluated for COVID-19 patients at different stages of the disease after having confirmed its…”
BackgroundMethodInfluentialQuantum machine learning for chemistry and physics
Sajjan, M., Li, J., Selvarajan, R., Sureshbabu, S. H., Kale, S. S., Gupta, R., Singh, V., & Kais, S. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00203e · Cited by 216
Gene regulatory network inference resources: A practical overview
Mercatelli, D., Scalambra, L., Triboli, L., Ray, F., & Giorgi, F. M. (2020) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2019.194430 · Cited by 161
Application of Computational Biology and Artificial Intelligence in Drug Design
Zhang, Y., Luo, M., Wu, P., Wu, S., Lee, T.-Y., & Bai, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113568 · Cited by 150
Towards artificial intelligence-enabled extracellular vesicle precision drug delivery
Greenberg, Z., Graim, K. S., & He, M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114974 · Cited by 175
A big data approach to the concordance of the toxicity of pharmaceuticals in animals and humans
Clark, M., & Steger-Hartmann, T. (2018) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2018.04.018 · Cited by 162
The landscape of small-molecule prodrugs
Fralish, Z., Chen, A., Khan, S. M., Zhou, P., & Reker, D. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00914-7 · Cited by 183
“Additionally, we analysed the turnover rate of prodrugs by mining their half-lives from DrugBank 15 and classified the 45 prodrugs for which data are available into groups (Fig.”
InfluentialA geometric deep learning framework for drug repositioning over heterogeneous information networks
Zhao, B.-W., Su, X.-R., Hu, P.-W., Ma, Y.-P., Zhou, X., & Hu, L. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac384 · Cited by 158
Saravanakumar, A., Sadighi, A., Ryu, R. J., & Akhlaghi, F. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00750-8 · Cited by 165
Pseudo Natural Products—Chemical Evolution of Natural Product Structure
Karageorgis, G., Foley, D. J., Laraia, L., Brakmann, S., & Waldmann, H. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202016575 · Cited by 165
Network medicine for disease module identification and drug repurposing with the NeDRex platform
Sadegh, S., Skelton, J., Anastasi, E., Bernett, J., Blumenthal, D. B., Galindez, G., Salgado-Albarrán, M., Lazareva, O., Flanagan, K., Cockell, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27138-2 · Cited by 173
Bragina, M. E., Daina, A., Perez, M. A. S., Michielin, O. A., & Zoete, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020811 · Cited by 176
“8, open data) that contains FDA-approved, experimental, investigational and withdrawn drugs, as well as illicit compounds and nutraceuticals [26]; (2) Ligand Expo that collects small molecules appearing in experimental structures deposited within the Protein DataBank [27]; (3) Chemical Entities of Biological Interest…”
BackgroundDARK Classics in Chemical Neuroscience: Psilocybin
Geiger, H. A., Wurst, M. G., & Daniels, R. N. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00186 · Cited by 141
Unravelling the antimicrobial action of antidepressants on gut commensal microbes
Ait Chait, Y., Mottawea, W., Tompkins, T. A., & Hammami, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-74934-9 · Cited by 153
Deep learning approaches for de novo drug design: An overview
Wang, M., Wang, Z., Sun, H., Wang, J., Shen, C., Weng, G., Chai, X., Li, H., Cao, D., & Hou, T. (2021) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2021.10.001 · Cited by 185
Towards the functional high-resolution coordination chemistry of blood plasma human serum albumin
Al-Harthi, S., Lachowicz, J. I., Nowakowski, M. E., Jaremko, M., & Jaremko, Ł. (2019) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2019.110716 · Cited by 168
Cornelissen, F. M. G., Markert, G., Deutsch, G., Antonara, M., Faaij, N., Bartelink, I. H., Noske, D. P., Vandertop, W. P., Bender, A., & Westerman, B. A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01824 · Cited by 172
Novel deep learning model for more accurate prediction of drug-drug interaction effects
Lee, G., Park, C., & Ahn, J. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-3013-0 · Cited by 166
Burley, S. K., Berman, H. M., Duarte, J. M., Feng, Z., Flatt, J. W., Hudson, B. P., Lowe, R., Peisach, E., Piehl, D. W., Rose, Y., et al. (2022) · Biomolecules · doi:10.3390/biom12101425 · Cited by 172
BioLiP2: an updated structure database for biologically relevant ligand–protein interactions
Zhang, C., Zhang, X., Freddolino, L., & Zhang, Y. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkad630 · Cited by 139
Gocho, Y., Liu, J., Hu, J., Yang, W., Dharia, N. V., Zhang, J., Shi, H., Du, G., John, A., Lin, T.-N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-020-00167-4 · Cited by 153
Predicting drug-target interaction network using deep learning model
You, J., McLeod, R. D., & Hu, P. (2019) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2019.03.016 · Cited by 150
Harding, S. D., Armstrong, J. F., Faccenda, E., Southan, C., Alexander, S. P. H., Davenport, A. P., Pawson, A. J., Spedding, M., Davies, J. A., & NC-IUPHAR (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab1010 · Cited by 149
“The file includes PubChem CID, PubChem SID, ChEMBL, ChEBI, UniProtKB, IUPAC, INN, CAS, DrugBank and DrugCentral identifiers (www.guidetopharmacology.org/ DATA/ligand id mapping.csv).”
InfluentialPathBank: a comprehensive pathway database for model organisms
Wishart, D. S., Li, C., Marcu, A., Badran, H., Pon, A., Budinski, Z., Patron, J., Lipton, D., Cao, X. D., Oler, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz861 · Cited by 156
Self-citationIn silico Methods for Design of Kinase Inhibitors as Anticancer Drugs
Gagić, Ž., Ružić, D., Djoković, N., Djikić, T., & Nikolic, K. M. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00873 · Cited by 160
“…QSAR pharmacophore model was developed from the structures of known inhibitors of MAPK1 (ERK2) and used for virtual screening of ZINC database (Irwin et al., 2012) that contains over 750 million compounds, DrugBank with 13,443 drugs (Wishart et al., 2018), NCI (https://cactus.nci.nih.gov/ ncidb2.”
MethodInfluentialHe, K., Mao, R., Lin, Q., Ruan, Y., Lan, X., Feng, M., & Cambria, E. (2025) · Information Fusion · doi:10.1016/j.inffus.2025.102963 · Cited by 147
Analysis of Benzenoid Substitution Patterns in Small Molecule Active Pharmaceutical Ingredients
Nilova, A., Campeau, L., Sherer, E. C., & Stuart, D. R. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00915 · Cited by 163
Predicting the frequencies of drug side effects
Galeano, D., Li, S., Gerstein, M., & Paccanaro, A. (2020) · Nature Communications · doi:10.1038/s41467-020-18305-y · Cited by 157
Comprehensive Survey of Recent Drug Discovery Using Deep Learning
Kim, J., Park, S., Min, D., & Kim, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189983 · Cited by 167
“DrugBank [216] 6566 4844 18,734 2020 https://go.”
A risk based assessment approach for chemical mixtures from wastewater treatment plant effluents
Finckh, S., Beckers, L., Busch, W., Carmona, E., Dulio, V., Kramer, L., Krauss, M. K. V., Posthuma, L., Schulze, T., Slootweg, J., et al. (2022) · Environment International · doi:10.1016/j.envint.2022.107234 · Cited by 155
“Compounds were assigned to their specific use groups based on the information available from databases (Drugbank, Pubchem, PPDB, and Wikipedia) and from literature.”
MethodQuinazolinones, the Winning Horse in Drug Discovery
Alsibaee, A. M., Al-Yousef, H. M., & Al-Salem, H. S. (2023) · Molecules · doi:10.3390/molecules28030978 · Cited by 146
“This drug has great efficacy and a good safety profile with few side effects such as dizziness, dry mouth, and nausea [43,44].”
BackgroundIs Target-Based Drug Discovery Efficient? Discovery and “Off-Target” Mechanisms of All Drugs
Sadri, A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01737 · Cited by 163
Ursu, O., Holmes, J., Bologa, C. G., Yang, J. J., Mathias, S. L., Stathias, V., Nguyen, D.-T., Schürer, S., & Oprea, T. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky963 · Cited by 142
“For example, while patent information from the FDA Orange Book is included in DrugBank (11), market exclusivity, pharmaceutical formulations and patent use codes are not available.”
BackgroundInfluentialA Survey of the Role of Nitrile Groups in Protein–Ligand Interactions
Wang, Y. E., Du, Y., & Huang, N. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0252 · Cited by 156
DrugRep: an automatic virtual screening server for drug repurposing
Gan, J.-H., Liu, J., Liu, Y., Chen, S., Dai, W., Xiao, Z. J., & Cao, Y. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00996-2 · Cited by 160
“…interactive view, 2D images, the molecular mass, the number of hydrogen bond donors, the number of hydrogen bond acceptors, and the number of rotatable bonds, the n-octanol-water partition coef fi cient (logP), drug targets, drug pharmacodynamics, hyperlinks to the related data [48, 59] and so on.”
BackgroundInfluentialSelf-citationZhao, J., Tian, S., Lu, D., Yang, J., Zeng, H., Zhang, F., Tu, D., Ge, G., Zheng, Y., Shi, T., et al. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153315 · Cited by 158
“For each compound, putative targets were acquired from four databases: DrugBank (Wishart et al., 2018), PubChem (Kim et al., 2016), STITCH (Search Tool for Interactions of Chemicals) (Kuhn et al., 2008), and ETCM (Xu et al., 2018).”
Kim, H., Kim, E., Lee, I., Bae, B., Park, M., & Nam, H. (2020) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-020-0049-y · Cited by 131
Artificial Intelligence in Pharmaceutical Sciences
Lu, M., Yin, J., Zhu, Q., Lin, G., Mou, M., Liu, F., Pan, Z., You, N., Lian, X., Li, F., et al. (2023) · Engineering · doi:10.1016/j.eng.2023.01.014 · Cited by 161
Thafar, M. A., Olayan, R. S., Ashoor, H., Albaradei, S., Bajic, V. B., Gao, X., Gojobori, T., & Essack, M. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00447-2 · Cited by 143
“We used biomedical literature and several reference databases, including KEGG [81, 82], DrugBank [83, 84], PubChem [85, 86], CheMBLE [87– 89], MATADOR [90], SuperTarget [90], Comparative Toxicogenomics Database (CTD) [91, 92], and the annotated database of common toxins and their targets (T3DB)…”
MethodColli, M. L., Ramos-Rodríguez, M., Nakayasu, E. S., Alvelos, M. I., Lopes, M., Hill, J. L. E., Turatsinze, J.-V., Coomans de Brachène, A., Russell, M. A., Raurell-Vila, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16327-0 · Cited by 140
Human melanocyte development and melanoma dedifferentiation at single-cell resolution
Belote, R. L., Le, D., Maynard, A., Lang, U. E., Sinclair, A., Lohman, B. K., Planells-Palop, V., Baskin, L., Tward, A. D., Darmanis, S., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00740-8 · Cited by 136
Self-citationInternational consensus statement on allergy and rhinology: Olfaction
Patel, Z. M., Holbrook, E. H., Turner, J. H., Adappa, N. D., Albers, M. W., Altundağ, A., Appenzeller, S., Costanzo, R. M., Croy, I., Davis, G. E., et al. (2022) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22929 · Cited by 160
A guide to maximizing the therapeutic potential of protein–polymer conjugates by rational design
Ko, J. H., & Maynard, H. D. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00606g · Cited by 142
A practical view of fine-mapping and gene prioritization in the post-genome-wide association era
Broekema, R. V., Bakker, O. B., & Jonkers, I. H. (2020) · Open Biology · doi:10.1098/rsob.190221 · Cited by 130
“Indeed, the genes and pathways associated with stronger or joint genetic effects are more likely candidates for drug interventions [120] (electronic supplementary material, table S1).”
BackgroundZeng, X., Zhu, S., Hou, Y., Zhang, P., Li, L., Li, J., Huang, L. F., Lewis, S. J., Nussinov, R., & Cheng, F. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa010 · Cited by 146
A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs
Girardi, E., César-Razquin, A., Lindinger, S., Papakostas, K., Konecka, J., Hemmerich, J., Kickinger, S., Kartnig, F., Gürtl, B., Klavins, K., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0483-3 · Cited by 133
Hufsky, F., Lamkiewicz, K., Almeida, A., Aouacheria, A., Arighi, C. N., Bateman, A. G., Baumbach, J., Beerenwinkel, N., Brandt, C., Cacciabue, M., et al. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa232 · Cited by 154
Vina-GPU 2.0: Further Accelerating AutoDock Vina and Its Derivatives with Graphics Processing Units
Ding, J., Tang, S., Mei, Z., Wang, L., Huang, Q., Hu, H., Ling, M., & Wu, J. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01504 · Cited by 161
Fang, J., Zhang, P., Wang, Q., Chiang, C.-W., Zhou, Y., Hou, Y., Xu, J., Chen, R., Zhang, B., Lewis, S. J., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00951-z · Cited by 140
Xiong, G., Yang, Z., Yi, J., Wang, N., Wang, L., Zhu, H., Wu, C., Lu, A., Chen, X., Liu, S., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkab880 · Cited by 133
Deng, Y., Ou, Y., Wu, B., Yang, Y., Jiang, Y., Huang, Y., Liu, Y., Tan, L., Dong, Q., Suckling, J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01507-9 · Cited by 149
Self-citationA proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population
Qu, Y., Feng, J., Wu, X., Bai, L., Xu, W., Zhu, L., Liu, Y., Xu, F., Zhang, X., Yang, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29577-x · Cited by 167
Self-citationAlphaFold2 protein structure prediction: Implications for drug discovery
Borkakoti, N., & Thornton, J. M. (2023) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102526 · Cited by 128
Patient-derived pancreatic cancer-on-a-chip recapitulates the tumor microenvironment
Haque, M. R., Wessel, C. R., Leary, D. D., Wang, C., Bhushan, A., & Bishehsari, F. (2022) · Microsystems & Nanoengineering · doi:10.1038/s41378-022-00370-6 · Cited by 137
Machine learning for perturbational single-cell omics
Ji, Y., Lotfollahi, M., Wolf, F. A., & Theis, F. J. (2021) · Cell Systems · doi:10.1016/j.cels.2021.05.016 · Cited by 137
ReDO_DB: the repurposing drugs in oncology database
Pantziarka, P., Verbaanderd, C., Sukhatme, V., Capistrano, R., Crispino, S., Gyawali, B., Rooman, I., Van Nuffel, A. M., Meheus, L., Sukhatme, V. P., et al. (2018) · ecancermedicalscience · doi:10.3332/ecancer.2018.886 · Cited by 136
“Wishart DS, Knox C, and Guo AC, et al (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets Nucleic Acids Res 36(Database Issue) D901–D906 https://doi.org/10.1093/nar/gkm958 PMCID: 2238889 14.”
MethodInfluentialHai, Y., Wei, M., Wang, C., Gu, Y., & Shao, C. (2021) · Marine Life Science & Technology · doi:10.1007/s42995-021-00101-2 · Cited by 142
Tian, S., Zhang, J., Yuan, S., Wang, Q., Lv, C., Wang, J., Fang, J., Fu, L., Yang, J., Zu, X., et al. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad027 · Cited by 148
Pan-cancer proteogenomics expands the landscape of therapeutic targets
Savage, S. R., Yi, X., Lei, J. T., Wen, B., Zhao, H., Liao, Y., Jaehnig, E. J., Somes, L. K., Shafer, P. W., Lee, T. D., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.039 · Cited by 152
Rahman, M. R., Islam, T., Zaman, T., Shahjaman, M., Karim, M. R., Huq, F., Quinn, J. M. W., Holsinger, R. M. D., Gov, E., & Moni, M. A. (2020) · Genomics · doi:10.1016/j.ygeno.2019.07.018 · Cited by 136
Detecting Potential Adverse Drug Reactions Using a Deep Neural Network Model
Wang, C.-S., Lin, P.-J., Cheng, C., Tai, S.-H., Yang, Y. K., & Chiang, J.-H. (2019) · Journal of Medical Internet Research · doi:10.2196/11016 · Cited by 147
“We utilized the biological features from DrugBank[26] to represent the biomolecular interactions and pathways.”
α-Branched amines by catalytic 1,1-addition of C–H bonds and aminating agents to terminal alkenes
Maity, S., Potter, T. J., & Ellman, J. A. (2019) · Nature Catalysis · doi:10.1038/s41929-019-0330-7 · Cited by 137
DrugComb update: a more comprehensive drug sensitivity data repository and analysis portal
Zheng, S., Aldahdooh, J., Shadbahr, T., Wang, Y., Aldahdooh, D., Bao, J., Wang, W., & Tang, J. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab438 · Cited by 127
Thioredoxin reductase as a pharmacological target
Bjørklund, G., Zou, L., Wang, J., Chasapis, C. T., & Peana, M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105854 · Cited by 141
Emerging technologies and their impact on regulatory science
Anklam, E., Bahl, M. I., Ball, R., Beger, R. D., Cohen, J. E., Fitzpatrick, S., Girard, P., Halamoda‐Kenzaoui, B., Hinton, D., Hirose, A., et al. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211052280 · Cited by 149
Self-citationAccelerating AutoDock Vina with GPUs
Tang, S., Chen, R., Mengru, L., Qingde, L., Zhu, Y., Ding, J., Wu, J., Haifeng, H., & Ming, L. (2022) · Molecules · doi:10.3390/molecules27093041 · Cited by 151
“To show the acceleration effect of our Vina-GPU in implementing real virtual screens of compound databases, a case was detailed on the receptor 1xm6 (PDBid) with the docking of DrugBank [37].”
MethodAfantitis, A., Melagraki, G., Isigonis, P., Tsoumanis, A., Varsou, D., Valsami‐Jones, E., Papadiamantis, A. G., Ellis, L. A., Sarimveis, H., Doganis, P., et al. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.02.023 · Cited by 135
“This generated large reference data sets such as connectivity map [152], TG-GATEs [51], DrugBank [184] and LINCS L1000 [66].”
MethodThe Medicinal Chemistry of Caffeine
Faudone, G., Arifi, S., & Merk, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00261 · Cited by 150
Emerging Building Blocks for Medicinal Chemistry: Recent Synthetic Advances
Grygorenko, O. O., Volochnyuk, D. M., & Vashchenko, B. V. (2021) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202100857 · Cited by 133
Amorim, A. M. B., Piochi, L. F., Gaspar, A. T., Preto, A. J., Rosário-Ferreira, N., & Moreira, I. S. (2024) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.3c00352 · Cited by 132
Chen, L., Hu, C., Hood, M., Zhang, X., Zhang, L., Kan, J., & Du, J. (2020) · Nutrients · doi:10.3390/nu12041193 · Cited by 131
“DrugBank contains detailed drug, drug-target, drug action and drug interaction information about FDA-approved drugs as well as experimental drugs [34].”
BackgroundMachine learning methods, databases and tools for drug combination prediction
Wu, L., Wen, Y., Leng, D., Zhang, Q., Dai, C., Wang, Z., Liu, Z., Yan, B., Zhang, Y., Wang, J., et al. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab355 · Cited by 126
VARIDT 1.0: variability of drug transporter database
Yin, J., Sun, W. C., Li, F., Hong, J., Li, X., Zhou, Y., Lu, Y., Liu, M., Zhang, X. Z., Chen, N., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz779 · Cited by 141
Yang, Z., Zhong, W., Lv, Q., & Chen, C. Y. (2022) · Chemical Science · doi:10.1039/d2sc02023h · Cited by 147
A Generative Approach to Materials Discovery, Design, and Optimization
Menon, D., & Ranganathan, R. (2022) · ACS Omega · doi:10.1021/acsomega.2c03264 · Cited by 121
Bang, D., Lim, S., Lee, S., & Kim, S. (2023) · Nature Communications · doi:10.1038/s41467-023-39301-y · Cited by 155
“The ATC codes were assigned to drugs using the information provided by Drugbank 46 .”
Application of the SwissDrugDesign Online Resources in Virtual Screening
Daina, A., & Zoete, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184612 · Cited by 142
Metadata
- Authors
- Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., Pon, A., Knox, C., & Wilson, M.
- Affiliations
- University of Alberta (CA)
- Corresponding author
- Wishart, David S
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-11-08
- Volume
- 46
- Issue
- D1
- Pages
- D1074-D1082
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC5753335
- OpenAlex
- W2767891136
- Cited by
- 8,404
- References
- 22
- Citations by year
- 2026: 617 · 2025: 929 · 2024: 1327 · 2023: 1363 · 2022: 1322 · 2021: 1175 · 2020: 957 · 2019: 502 · 2018: 201 · 2017: 5
- FWCI
- 343.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Genome Canada
- Genome Alberta
- Health Canada
- Canadian Institutes of Health Research
- National Human Genome Research Institute
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- DrugBank, drug databases, drug-drug interactions, food-drug interactions, therapeutic target, drug mechanisms, drug indications, pharmacometabolomics, pharmacoproteomics, drug repurposing, clinical trials, investigational drugs
- MeSH terms
- Drug Interactions, User-Computer Interface, Food-Drug Interactions, Polymorphism, Single Nucleotide, Metabolome, Transcriptome, Databases, Pharmaceutical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

